Petefészekrák: nyitott vizsgálatok itt: Brazília
17 trials · From ClinicalTrials.gov, checked 2026. nov. 10.. Ask the study team whether a trial fits you.
3. fázisToborozTrial-stage medicine
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Where
- Belo Horizonte, Curitiba, Goiânia, Porto Alegre, Rio de Janeiro, São José do Rio Preto, São Paulo
- Age
- 18 év and over
- People
- 420 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500Regiszter frissítve: 2026-11-09
3. fázisToborozTrial-stage medicine
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
- Where
- Fortaleza, Itajaí, Jaú, Natal, Porto Alegre, Rio de Janeiro, Salvador, São Paulo
- Age
- 18 év and over
- People
- 950 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07851025EU 2026-526895-22-00Regiszter frissítve: 2026-11-06
3. fázisToborozTrial-stage medicine
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Belém, Belo Horizonte, Florianópolis, Lago Sul, Rio de Janeiro, Salvador, São Caetano do Sul
- Age
- 18 év and over
- People
- 1630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804EU 2025-522255-25-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Where
- Belo Horizonte, Blumenau, Jaú, Natal, Porto Alegre, Santo André, São José do Rio Preto, São Paulo
- Age
- 18 év and over
- People
- 582 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06819007EU 2024-516982-35-00Regiszter frissítve: 2026-10-28
2/3. fázisToborozTrial-stage medicine
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Where
- Belo Horizonte, Porto Alegre, Rio de Janeiro
- Age
- 18 év and over
- People
- 860 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06161025EU 2023-507914-28-00Regiszter frissítve: 2026-10-26
1/2. fázisToborozTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Barretos, Florianópolis, Jaú, Porto Alegre
- Age
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064EU 2023-509632-26-00Regiszter frissítve: 2026-10-26
3. fázisCsak meghívásosTrial-stage medicine
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
- Where
- Fortaleza, Goiânia, Londrina, Porto Alegre, Porto Velho, Rio de Janeiro, Santo André, São Paulo
- Age
- 18 év to 51 év
- People
- 250 worldwide
- Run by
- Tolmar Inc.
See details and how to joinNCT05645536Regiszter frissítve: 2026-10-23
3. fázisToborozTrial-stage medicine
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
- Where
- Porto Alegre, São Caetano do Sul, São José do Rio Preto, São José dos Campos, São Paulo, Teresina, Vitória
- Age
- 18 év and over
- People
- 600 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07816666EU 2026-526776-23-00Regiszter frissítve: 2026-10-16
3. fázisToborozTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Where
- Lages, Natal, Porto Alegre, Rio de Janeiro, São José do Rio Preto, São Paulo
- Age
- 18 év and over
- People
- 770 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06824467EU 2023-508015-23-00Regiszter frissítve: 2026-10-13
3. fázisToborozTrial-stage medicine
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Where
- Lages, Natal, Porto Alegre, Salvador, São José do Rio Preto, São Paulo
- Age
- 18 év and over
- People
- 900 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07318558EU 2023-508047-40-00Regiszter frissítve: 2026-10-13
1/2. fázisToborozTrial-stage medicine
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Where
- Barretos, Porto Alegre, São Paulo, Sorocaba
- Age
- 18 év and over
- People
- 612 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT04590326EU 2022-501904-83-00Regiszter frissítve: 2026-09-24
No phaseToborozResearch participation
Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries
- Where
- São Paulo
- Age
- 18 év and over
- People
- 1000 worldwide
- Run by
- AbbVie
See details and how to joinNCT07539844Regiszter frissítve: 2026-09-14
No phaseToborzás még nem indultResearch participation
Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients
- Where
- Belo Horizonte, Campo Grande, Lages, Natal, Porto Alegre, Recife, Rio de Janeiro, São Paulo
- Age
- 18 év and over
- People
- 320 worldwide
- Run by
- Latin American Cooperative Oncology Group
See details and how to joinNCT07771400Regiszter frissítve: 2026-08-25
3. fázisToborozTrial-stage medicine
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Where
- Barretos, Bela Vista, Curitiba, Goiânia, Natal, Porto Alegre, Porto Velho, Rio de Janeiro, São José do Rio Preto, São Paulo
- Age
- 18 év and over
- People
- 1100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07218809EU 2025-520466-22-00Regiszter frissítve: 2026-07-21
No phaseToborozResearch participation
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
- Where
- São Paulo
- Age
- 25 év to 50 év
- People
- 3000 worldwide
- Run by
- University Medical Center Nijmegen
See details and how to joinNCT04294927Regiszter frissítve: 2026-04-06
3. fázisToborozTrial-stage medicine
Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)
- Where
- São Paulo
- Age
- 18 év to 60 év
- People
- 140
- Run by
- University of Sao Paulo General Hospital
See details and how to joinNCT06343870Regiszter frissítve: 2025-12-29
No phaseToborzás még nem indultResearch participation
Proteomic Analysis of Patients Undergoing Bariatric Surgery
- Where
- Recife
- Age
- 18 év and over
- People
- 103
- Run by
- Universidade Federal de Pernambuco
See details and how to joinNCT06787807Regiszter frissítve: 2025-01-22
Minden vizsgálat (Petefészekrák) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.